A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

NCT05769725 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Serplulimab,Gastric Cancer, Adjuvant Therapy

Interventions

DRUG: Serplulimab
DRUG: Docetaxel
DRUG: S1

Sponsor

RenJi Hospital